Copy to clipboard 
The first patient has been treated with Ossium Health’s newly-released OssiGraft viable bone matrix (VBM) allograft in an ankle surgery, representing Ossium’s entrance into the orthopedic biologics market.
Ossium’s core product is cryopreserved bone marrow derived from the vertebral columns of organ donors. This device is used in curative transplant procedures for blood cancer patients who don’t have a bone marrow match in the living donor registry. OssiGraft was born out of the idea that the bone grindings remaining after the bone marrow elution, which previously went unused, could have a therapeutic orthopedic purpose. Ossium carefully adapted and refined the processing steps to produce OssiGraft in addition to bone marrow.
Ossium’s stringent screening, testing and processing controls already in place to ensure the quality and safety of Ossium’s bone marrow product exceed regulatory requirements for tissue products. Since OssiGraft donors must meet the screening criteria for cell therapies in addition to tissue products, OssiGraft donors are far younger than similar products on the market, further reducing disease transmission risks. Lastly, Ossium ensures finished product safety by using a best-in-class decontamination process with a cocktail of antibiotics and an antimycotic.
OssiGraft is in use across the East Coast and will soon be available throughout the United States.
Building on the success of OssiGraft, Ossium is now working on its next-generation VBM, which will be introduced in 2024.
“We’ve always strived to maximize the positive impact of each organ donor’s generous gift,” said Kevin Caldwell, Ossium’s CEO, Co-Founder & President. “First, we developed a life-saving product from organ donor bone marrow, which didn’t previously have an established therapeutic application. With the development of OssiGraft, we’re expanding the impact of each donor’s gift even further and advancing our company mission.”
Source: Ossium Health
The first patient has been treated with Ossium Health’s newly-released OssiGraft viable bone matrix (VBM) allograft in an ankle surgery, representing Ossium’s entrance into the orthopedic biologics market.
Ossium’s core product is cryopreserved bone marrow derived from the vertebral columns of organ donors. This device is used in curative...
The first patient has been treated with Ossium Health’s newly-released OssiGraft viable bone matrix (VBM) allograft in an ankle surgery, representing Ossium’s entrance into the orthopedic biologics market.
Ossium’s core product is cryopreserved bone marrow derived from the vertebral columns of organ donors. This device is used in curative transplant procedures for blood cancer patients who don’t have a bone marrow match in the living donor registry. OssiGraft was born out of the idea that the bone grindings remaining after the bone marrow elution, which previously went unused, could have a therapeutic orthopedic purpose. Ossium carefully adapted and refined the processing steps to produce OssiGraft in addition to bone marrow.
Ossium’s stringent screening, testing and processing controls already in place to ensure the quality and safety of Ossium’s bone marrow product exceed regulatory requirements for tissue products. Since OssiGraft donors must meet the screening criteria for cell therapies in addition to tissue products, OssiGraft donors are far younger than similar products on the market, further reducing disease transmission risks. Lastly, Ossium ensures finished product safety by using a best-in-class decontamination process with a cocktail of antibiotics and an antimycotic.
OssiGraft is in use across the East Coast and will soon be available throughout the United States.
Building on the success of OssiGraft, Ossium is now working on its next-generation VBM, which will be introduced in 2024.
“We’ve always strived to maximize the positive impact of each organ donor’s generous gift,” said Kevin Caldwell, Ossium’s CEO, Co-Founder & President. “First, we developed a life-saving product from organ donor bone marrow, which didn’t previously have an established therapeutic application. With the development of OssiGraft, we’re expanding the impact of each donor’s gift even further and advancing our company mission.”
Source: Ossium Health
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
